Loading...

QNRX QUOIN PHARMACEUTICALS LTD US FDA Inspections 8-K Filing

QN P

QNRX

QUOIN PHARMACEUTICALS LTD

(QNRX)

2025 8-K

Show Summary

Summary

Shareholder Meeting Results

Financial Statements

Pre-Market Approval

Investor Meetings

Compensatory Arrangements o...

Clinical Trials

Pre-Market Approval

Financial Statements

Changes in capital structure

ADS Ratio Change

ADS Reverse Split

Positive Clinical Data

Financial Results

Positive Clinical Data

Netherton Campaign

Clinical Data Update

Positive Clinical Data

Clinical Data Update

Public Offering

FDA Study Clearance

Annual Meeting Outcomes

Q3 Financial Results

Nasdaq Compliance

AGM Announcement

Q2 2024 Results

Shareholder Vote

Financial Results

Public Offering

Merger and Sale

Purchase Agreement with Alu...

FDA Clearance for Clinical ...

Financial Results Announcement

Amendments and Reverse Split

Annual General Meeting

Agreement with Farma Mondo

Financial Results Announcement

Ratio Change for ADSs

Exemption from Quorum Requi...

Financial Results

Financial Results

Securities Purchase Agreement

External Links:

On May 20, 2025, Quoin Pharmaceuticals Ltd. announced that it has received Orphan Drug Designation in Europe for its lead product QRX003, aimed at treating Netherton Syndrome.

AI Assistant

QUOIN PHARMACEUTICALS LTD

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.